: A Prospective, Open Label, Randomized, Controlled, Clinical Study To Evaluate The Safety And Efficacy Of Cardamom Extract (500mg tablet) In Mild To Modrate Covid-19 Adult Patients

Zum Heilen Diagnostic Therapeutics ZH DT0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年2月21日

试验速览

暂无简介。

•1.Subjects aged 18-65 years of age and of either sex
•2.Subjects who are willing to give consent to the study
•3.COVID-19 positive clinical symptoms and (subsequently) confirmed by the current recommended confirmatory test (RT-PCR).
•4.Mild to Moderate disease (NEWS score Less than/equal to 8)
•5.Can take oral medicines
•6.Subject willing to abide by and comply with the study protocol

•1.Age less than 18 years and more than 65 years
•2.Pregnancy and lactation
•3.Severe or complicated course of COVID-19 disease
•4.Presence of acute hypoxic respiratory failure/ need for Intensive care unit (ICU) stay/ Patients who need mechanical ventilation.
•5.Any uncontrolled systemic disease, infection
•6.Those with serious Cardiovascular, Cerebrovascular, Respiratory, Liver or Renal disease or any other disorder.
•7.Other conditions, which in the opinion of the investigators makes the patient unsuitable for enrolment or could interfere in adherence to of the study protocol

发起方

Zum Heilen Diagnostic Therapeutics ZH DT